Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 3:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 49 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: COVID Convalescent Plasma Clear all
Completed Phase 1 Interventional Results available

COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.

NCT04397757
View directory record Official record
Conditions
COVID-19
Interventions
COVID-19 Convalescent Plasma
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 7, 2026, 3:33 AM EDT
Terminated Phase 2 Interventional Results available

Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection

NCT04343755
View directory record Official record
Conditions
COVID-19
Interventions
Convalescent Plasma
Biological
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 7, 2026, 3:33 AM EDT
Terminated Phase 2 Interventional Results available

ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS)

NCT04432272
View directory record Official record
Conditions
COVID-19, Severe Acute Respiratory Syndrome (SARS), Coronavirus Infections
Interventions
COVID-19 convalescent plasma
Biological
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 7, 2026, 3:33 AM EDT
Terminated Phase 2 Interventional Results available

Use of Convalescent Plasma for COVID-19

NCT04408040
View directory record Official record
Conditions
COVID
Interventions
Convalescent Plasma
Biological
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 7, 2026, 3:33 AM EDT
Recruiting Phase 2 Interventional

Convalescent Plasma as a Possible Treatment for COVID-19

NCT04442191
View directory record Official record
Conditions
COVID-19
Interventions
Convalescent plasma, Placebo
Biological
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Oct 7, 2026, 3:33 AM EDT
No Longer Available No phase listed Expanded access

Convalescent Plasma for the Treatment of Patients With COVID-19

NCT04372368
View directory record Official record
Conditions
COVID-19, SARS-CoV 2
Interventions
COVID-19 Convalescent Plasma
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
U.S. locations
6
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2020 · Synced Oct 7, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia

NCT04374565
View directory record Official record
Conditions
Corona Virus Infection, SARS-CoV 2, SARS Pneumonia, Pneumonia
Interventions
High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 1, 2022 · Synced Oct 7, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

Plasma Therapy of COVID-19 in Severely Ill Patients

NCT04359810
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
Convalescent Plasma (anti-SARS-CoV-2 plasma), Non-convalescent Plasma (control plasma)
Biological
Lead sponsor
Max O'Donnell
Other
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 7, 2026, 3:33 AM EDT
Completed Not applicable Interventional Results available

Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers

NCT04334876
View directory record Official record
Conditions
SARS-CoV-2
Interventions
SARS-CoV-2 IgG Antibody Testing Kit
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 7, 2026, 3:33 AM EDT
Completed No phase listed Observational Results available

Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19

NCT04545047
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19)
Interventions
COVID-19 convalescent plasma
Biological
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 80 Years
Enrollment
5,044 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 7, 2026, 3:33 AM EDT
Completed Phase 3 Interventional Results available

Convalescent Plasma in Outpatients With COVID-19

NCT04355767
View directory record Official record
Conditions
Covid19
Interventions
Convalescent Plasma, Saline
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
53
States / cities
Chandler, Arizona • Phoenix, Arizona • La Jolla, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 7, 2026, 3:33 AM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 7, 2026, 3:33 AM EDT
Not listed Phase 1 Interventional

Covid-19 Convalescent Plasma as Prevention and Treatment for Children With Underlying Medical Conditions

NCT04462848
View directory record Official record
Conditions
Corona Virus Infection
Interventions
anti-SARS-CoV-2 human convalescent plasma
Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
1 Month to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 7, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Convalescent Plasma to Stem Coronavirus (CSSC-001)

NCT04323800
View directory record Official record
Conditions
Coronavirus, Convalescence
Interventions
Anti- SARS-CoV-2 Plasma, SARS-CoV-2 non-immune Plasma
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
25
States / cities
Birmingham, Alabama • Whiteriver, Arizona • La Jolla, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Oct 7, 2026, 3:33 AM EDT
Completed Phase 3 Interventional Results available

Convalescent Plasma Collection and Treatment in Pediatrics and Adults

NCT04376034
View directory record Official record
Conditions
COVID19, Coronavirus Infection, Coronavirus, Virus Diseases, RNA Virus Infections
Interventions
Convalescent Plasma
Biological
Lead sponsor
West Virginia University
Other
Eligibility
31 Days and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 7, 2026, 3:33 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma

NCT04502472
View directory record Official record
Conditions
Covid-19
Interventions
Convalescent plasma transfusion
Biological
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 7, 2026, 3:33 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development

NCT04956445
View directory record Official record
Conditions
Covid19
Interventions
Not listed
Lead sponsor
Tulane University
Other
Eligibility
6 Months to 120 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
2
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 7, 2026, 3:33 AM EDT
Terminated Phase 3 Interventional Results available

VA CoronavirUs Research and Efficacy Studies-1

NCT04539275
View directory record Official record
Conditions
COVID-19
Interventions
Convalescent Plasma, Masked Saline Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2022 · Synced Oct 7, 2026, 3:33 AM EDT
Completed Not applicable Interventional

COVID-19 Plasma Collection

NCT04344015
View directory record Official record
Conditions
COVID-19
Interventions
Plasma Donation
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 7, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients

NCT04354831
View directory record Official record
Conditions
COVID-19
Interventions
anti-SARS-CoV-2 convalescent plasma
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Oct 7, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

Coronavirus Disease 2019 (COVID-19) Antibody Plasma Research Study in Hospitalized Patients

NCT04524507
View directory record Official record
Conditions
COVID-19
Interventions
High-titer Convalescent COVID-19 Plasma (CCP1), Standard-titer Convalescent COVID-19 plasma (CCP2)
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 7, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy and Safety of MAS825 in Patients With COVID-19

NCT04382651
View directory record Official record
Conditions
COVID-19 Pneumonia, Impaired Respiratory Function
Interventions
MAS825, Placebo, Standard of Care (SoC)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
21
States / cities
Chula Vista, California • Glendale, California • Irvine, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 7, 2026, 3:33 AM EDT
Completed Phase 2 Interventional Results available

Convalescent Plasma to Limit SARS-CoV-2 Associated Complications

NCT04373460
View directory record Official record
Conditions
SARS-CoV 2
Interventions
SARS-CoV-2 convalescent plasma, Plasma from a volunteer donor
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
1,225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
29
States / cities
Birmingham, Alabama • Chinle, Arizona • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 7, 2026, 3:33 AM EDT
Completed Phase 1 Interventional Results available

Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19)

NCT04377672
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
Anti-SARS-CoV-2 Human Convalescent Plasma
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
1 Month to 18 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 7, 2026, 3:33 AM EDT